BFRI

News Biofrontera Q2 Revenue Jumps 15%

14d ago

News Biofrontera targets cash flow breakeven in 2026 while aiming for 80%-85% gross margin

19d ago

News Biofrontera outlines 80%-85% gross margin target for 2026 following strategic asset acquisition

74d ago

SEC filing BFRI Reports $17.1M Q4 Rev, $4.6M Op Income, $6.4M Cash, Ameluz PDT FDA sNDA Accepted, Phase 3 AK Success, $3M Xepi Sale

75d ago

SEC filing BFRI Announces Positive Phase 3 Results for Ameluz® PDT, Achieving 45.6% Complete Clearance Rate, Plans sNDA Submission Q3 2026

113d ago

Scanner Unusual volume (2.3x average)

119d ago